Latest Articles and Analysis

On April 24, 2026, the Substance Abuse and Mental Health Services Administration (SAMHSA) issued a Dear Colleague letter that withdraws federal funding eligibility from fentanyl test strips, sterile...

Q2 2024 Watch: Prior authorization rollbacks in Medicaid HCV programs; ADAP and assistance program coverage.

Q1 2024 Watch: Pandemic Medicaid protections ended; millions lost coverage; ADAP and veterans updates.

Opioid settlement funds allocation overview: oversight and community impact considerations.

Q2 2023 Watch: Braidwood decision impacts PrEP coverage; ADAP coverage analysis and Medicaid program updates.

Xylazine contamination of drug supply demands harm reduction response including safe consumption sites.

DOJ clarifies ADA protections for people with opioid use disorder against discrimination.

MAT Act removes X-waiver requirements, expanding buprenorphine access especially in rural communities.

Q4 2021 Watch covering HCV drug formulary updates, ADAP and Medicaid changes, and pandemic impact on care.

31,000 Veterans with HIV face unique barriers including comorbidities and HCV rates 3x the general population.

Q3 2021 quarterly review of HCV drug access across ADAPs and Medicaid with harm reduction program updates.